
Altimmune (ALT) Stock Forecast & Price Target
Altimmune (ALT) Analyst Ratings
Bulls say
Altimmune Inc. possesses a favorable outlook due to the increasing interest in metabolic dysfunction-associated steatohepatitis (MASH) highlighted by Novo's acquisition of Akero Therapeutics, suggesting a strong market potential for innovative treatments like pemvidutide. The dual GLP-1/glucagon mechanism of pemvidutide is positioned to deliver significant therapeutic benefits, including rapid resolution of MASH and improvements in liver health metrics, emphasizing its competitive edge in the pipeline of metabolic disease therapies. Additionally, strategic leadership enhancements within the company and the alignment of their clinical data with market trends bolster confidence in pemvidutide's ability to succeed during pivotal upcoming clinical milestones.
Bears say
Altimmune Inc faces several significant risks that contribute to a negative outlook on its stock. The clinical development of pemvidutide is burdened by uncertainties related to its efficacy and safety, along with intense competition in the biopharmaceutical sector, which could hinder commercialization efforts. Additionally, potential challenges in securing reimbursement, pricing pressures, and broader market risks, including capital dilution and disruptions from external events like the COVID-19 pandemic and geopolitical tensions, further compound the outlook for the company.
This aggregate rating is based on analysts' research of Altimmune and is not a guaranteed prediction by Public.com or investment advice.
Altimmune (ALT) Analyst Forecast & Price Prediction
Start investing in Altimmune (ALT)
Order type
Buy in
Order amount
Est. shares
0 shares